Human Blood Cell Disorders Tissue Bank

Recruiting

• Conditions: Lymphoid, Myeloid and Erythroid Proliferative Disease; Human Blood Cell Disorders

• Registration Number: NCT00902447
• Lead Sponsor: Northwell Health

Brief Summary

The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04
• Study First Submitted: 2009-05-13
• Study First Submitted QC: 2009-05-14
• Study First Posted: 2009-05-15
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-25
• Last Update Posted: 2024-03-27
• Primary Completion: 2030-01
• Study Completion: 2035-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

• Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent.
• Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care.
• Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.

Exclusion Criteria

• Patients who are known to be anemic, with hemoglobin <8.0g/dl.
• Patients who are known to be infected with HIV.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions.	Indefinite

Secondary Outcome Measures

Name	Time	Method
Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future.	Indefinite

Trial Locations

Locations (1)

The Feinstein Institute for Medical Research; 🇺🇸 Manhasset, New York, United States